成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 100299-08-9 Chemical Structure| 100299-08-9
Chemical Structure| 100299-08-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 100299-08-9

,{[proInfo.pro_purity]}

Pemirolast potassium is an antagonist of histamine H1 and mast cell stabilizer with antiallergic effect.

Synonyms: BMY 26517; TWT-8152; TBX

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Pemirolast potassium

CAS No. :100299-08-9
Formula : C10H7KN6O
M.W : 266.30
SMILES Code : O=C1C(C2=N[N-]N=N2)=CN=C3N1C=CC=C3C.[K+]
Synonyms :
BMY 26517; TWT-8152; TBX
MDL No. :MFCD01690051
InChI Key :NMMVKSMGBDRONO-UHFFFAOYSA-N
Pubchem ID :443866

Safety of Pemirolast potassium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H361-H362
Precautionary Statements:P501-P263-P260-P270-P202-P201-P264-P280-P308+P313-P301+P312+P330-P405

Related Pathways of Pemirolast potassium

GPCR

Isoform Comparison

Biological Activity

Target
  • H1 receptor

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
BALB/c mice Allergic conjunctivitis model Ophthalmic administration 0.1% (w/v) Once daily for 14 days To evaluate the pharmacodynamic effect of Pemirolast Potassium in situ gels on allergic conjunctivitis, the results showed that the in situ gels were highly efficient in suppressing inflammatory symptoms and improving ocular bioavailability. PMC8140898

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02609334 Asthma Phase 2 Completed - Denmark ... More >> Hvidovre Hospital Hvidovre, Denmark, 2650 Bisbebjerg Hospital K?benhavn NV, Denmark, 2400 Less <<
NCT03119714 Allergic Asthma Phase 2 Recruiting April 2018 Sweden ... More >> Lung and Allergy Research Unit C2-88 Karolinska University Hospital Huddinge Recruiting Stockholm, Sweden, 14186 Contact: Barbro Dahlén, MD,PhD ?? +46858586785 ?? barbro.dahlen@ki.se ?? Contact: Nikolaos Lazarinis, MD ?? +46768760476 ?? nikolaos.lazarinis@ki.se Less <<
NCT02517372 Healthy Volunteers Phase 1 Completed - -
NCT02615080 Asthma Phase 2 Completed - Bulgaria ... More >> MHAT St. Ivan Rilski-2003 Ltd., Department of Internal Medicine Dupnitsa, Bulgaria, 2600 SHATPPD - Pazardzhik EOOD, Department of phthisiatrics pneumonia and pulmonary functional diagnostics Pazardzhik, Bulgaria, 4400 Medical Center - Razgrad OOD, Office of Pneumonology and Phthisiatry Razgrad, Bulgaria, 7200 Medical Center Smolyan OOD, Office of Clinical Allergology Smolyan, Bulgaria, 4700 First MHAT - Sofia EAD, Third Department of Internal Medicine Sofia, Bulgaria, 1000 MHAT Lyulin EAD, Department of Internal Medicine Sofia, Bulgaria, 1336 SHATPPD Vratsa Ltd, Department of Pneumology Vratza, Bulgaria, 3000 Denmark Aalborg Universitetshospital Aalborg, Denmark, 9000 Hvidovre Hospital Hvidovre, Denmark, 2650 Bisbebjerg Hospital K?benhavn NV, Denmark, 2400 N?stved Sygehus, Lungemedinsk afdeling N?stved, Denmark, 4700 Regionshospitalet Silkeborg Silkeborg, Denmark, 8600 Poland Centrum Badań Klinicznych PI-House Sp. Z O.O. Gdańsk, Poland, 80-546 Medica Pro Familia Katowice, Poland, 40-954 NZOZ Centrum Medcyczne ProMiMed Kraków, Poland, 31-637 Medica Pro Familia Krákow, Poland, 30-002 Clinical Best Solution Lublin, Poland, 20-045 NZOZ ALERGO-MED. Specjalistyczna Przychodnia Lekarska Poznan, Poland, 60-823 Medica Pro Familia Warszawa, Poland, 01-868 Centrum Medyczne Oporów Wroclaw, Poland, 52-416 United Kingdom The Medicines Evaluation Unit (MEU) Ltd Manchester, United Kingdom, M23 9QZ Medinova North London Clinical Studies Center Northwood, United Kingdom, HA6 2RN Medinova East London Clinical Studies Centre Romford, United Kingdom, RM1 3LT Medinova South London Clinical Studies Centre Sidcup, United Kingdom, DA14 6LT Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.76mL

0.75mL

0.38mL

18.78mL

3.76mL

1.88mL

37.55mL

7.51mL

3.76mL

References

[1]Tatsushima Y, Egashira N, et al. Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol. 2011 Jul 1;661(1-3):57-62.

[2]Kemp JP, Bernstein IL, et al. Pemirolast, a new oral nonbronchodilator drug for chronic asthma. Ann Allergy. 1992 Jun;68(6):488-91.

[3]Gohda T, Ra C, Hamada C, Tsuge T, Kawachi H, Tomino Y. Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis. Arzneimittelforschung. 2008;58(1):18-23

[4]Shulman DG. Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study. Adv Ther. 2003 Jan-Feb;20(1):31-40

[5]Yoshinuma M. [Preventive mechanisms and effects of pemirolast potassium on restenosis after percutaneous transluminal coronary angioplasty: serial coronary angiography and intravascular ultrasound studies]. J Cardiol. 1999 Feb;33(2):81-8. Japanese

[6]Minami K, Hossen MA, Kamei C. Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats. Biol Pharm Bull. 2005 Mar;28(3):473-6

[7]Fujimiya H, Nakashima S, Kumada T, Nakamura Y, Miyata H, Nozawa Y. An antiallergic drug, pemirolast potassium, inhibits inositol 1,4,5-trisphosphate production and Ca2+ mobilization in antigen-stimulated rat basophilic leukemia (RBL-2H3) cells. Arerugi. 1994 Feb;43(2 Pt 1):142-51

 

Historical Records

Categories